Korsana Biosciences (KRSA) Q3 2025 earnings summary

Executive summary

• Strategic focus shifted to building a neuropsychiatric pipeline, with an individualized treatment-resistant depression (TRD) therapy prioritized as the foundational candidate under a September MIT license. One employee and specialist consultants support operations.

• Q3 revenue rose to $875k, while the nine-month net loss narrowed to $2.7m from $3.6m; cash was $4.6m at quarter-end, with substantial doubt about continuing as a going concern.

Financial highlights

• Q3 2025 revenue was $875k versus $194k YoY; nine-month revenue was $1.05m versus $194k, driven by Akebia material sales and olinciguat option-related fees.

• Q3 operating expenses rose 42% YoY to $1.88m; nine-month expenses rose 20% to $5.18m, including higher consulting, outside services, and legal costs.

• Q3 net loss was $976k versus $723k YoY; nine-month net loss improved to $2.73m from $3.59m, including a $1.3m insurance recovery in 2025.

• Nine-month operating cash use was $1.7m versus $4.7m; financing provided $3.1m in 2025, compared with no financing activity in the prior-year period.

Outlook and guidance

• September 30 cash and cash equivalents are expected to fund operations into Q2 2026; additional funding is needed to sustain operations amid expected ongoing losses.

• Plans to address funding needs include reducing spending and pursuing additional capital; management assessed successful funding or adequate cost reductions as reasonably possible but less than probable.

• Development expenses and funding needs may fluctuate with candidate progress, regulatory review, strategic actions, and the timing of potential licensing, milestone, and royalty receipts.